Reprograming Yeast for Anti-Cancer Vinblastine Synthesis

Tian Ma,Zixin Deng

DOI: https://doi.org/10.1093/lifemeta/loac024

2022-01-01

Life Metabolism

Abstract:In a recent study published in Nature, Zhang et al. employed an innovative approach by reprogramming and engineering yeast strain for combined biosynthesis of vindoline and catharanthine, followed by an additional in vitro chemical step for the successful synthesis of the anti-cancer vinblastine.

What problem does this paper attempt to address?

Novel Strategy to Improve Vanillin Tolerance and Ethanol Fermentation Performances of Saccharomycere Cerevisiae Strains.

Dao-Qiong Zheng,Xin-Na Jin,Ke Zhang,Ya-Hong Fang,Xue-Chang Wu

DOI: https://doi.org/10.1016/j.biortech.2017.01.040

IF: 11.4

2017-01-01

Bioresource Technology

Abstract:The aim of this work was to develop a novel strategy for improving the vanillin tolerance and ethanol fermentation performances of Saccharomyces cerevisiae strains. Isogeneic diploid, triploid, and tetraploid S. cerevisiae strains were generated by genome duplication of haploid strain CEN.PK2-1C. Ploidy increments improved vanillin tolerance and diminished proliferation capability. Antimitotic drug methyl benzimidazol-2-ylcarbamate (MBC) was used to introduce chromosomal aberrations into the tetraploid S. cerevisiae strain. Interestingly, aneuploid mutants with DNA contents between triploid and tetraploid were more resistant to vanillin and showed faster ethanol fermentation rates than all euploid strains. The physiological characteristics of these mutants suggest that higher bioconversion capacities of vanillin and ergosterol contents might contribute to improved vanillin tolerance. This study demonstrates that genome duplication and MBC treatment is a powerful strategy to improve the vanillin tolerance of yeast strains.
De Novo Biosynthesis of Vindoline and Catharanthine in Saccharomyces cerevisiae

Di Gao,Tengfei Liu,Jucan Gao,Junhao Xu,Yuanwei Gou,Yingjia Pan,Dongfang Li,Cuifang Ye,Ronghui Pan,Lei Huang,Zhinan Xu,Jiazhang Lian

DOI: https://doi.org/10.34133/bdr.0002

2022-12-26

Abstract:Vinblastine has been used clinically as one of the most potent therapeutics for the treatment of several types of cancer. However, the traditional plant extraction method suffers from unreliable supply, low abundance, and extremely high cost. Here, we use synthetic biology approach to engineer Saccharomyces cerevisiae for de novo biosynthesis of vindoline and catharanthine, which can be coupled chemically or biologically to vinblastine. On the basis of a platform strain with sufficient supply of precursors and cofactors for biosynthesis, we reconstituted, debottlenecked, and optimized the biosynthetic pathways for the production of vindoline and catharanthine. The vindoline biosynthetic pathway represents one of the most complicated pathways ever reconstituted in microbial cell factories. Using shake flask fermentation, our engineered yeast strains were able to produce catharanthine and vindoline at a titer of 527.1 and 305.1 μg·liter-1, respectively, without accumulating detectable amount of pathway intermediates. This study establishes a representative example for the production of valuable plant natural products in yeast.
Fields to fermentors: Brewing botanical chemotherapeutic precursors using genetically engineered yeast

Prashanth Srinivasan,Christina D Smolke

DOI: https://doi.org/10.1016/j.medj.2022.10.006

2022-11-11

Med

Abstract:Plants are a rich source of chemotherapeutics and other essential medicines, but plant-based drug supply chains are unsustainable. Writing in Nature, Zhang et al.1 demonstrated a proof-of-concept alternate source of the anticancer drug vinblastine by engineering yeast to convert sugar and amino acids into its direct precursors, catharanthine and vindoline.
Enhanced bioproduction of anticancer precursor vindoline by yeast cell factories

Natalja Kulagina,Grégory Guirimand,Céline Melin,Pamela Lemos‐Cruz,Ines Carqueijeiro,Johan‐Owen De Craene,Audrey Oudin,Vladimir Heredia,Konstantinos Koudounas,Marianne Unlubayir,Arnaud Lanoue,Nadine Imbault,Benoit St‐Pierre,Nicolas Papon,Marc Clastre,Nathalie Giglioli‐Guivarc’h,Jillian Marc,Sébastien Besseau,Vincent Courdavault

DOI: https://doi.org/10.1111/1751-7915.13898

2021-07-24

Microbial Biotechnology

Abstract:The pharmaceutical industry faces a growing demand and recurrent shortages in many anticancer plant drugs given their extensive use in human chemotherapy. Efficient alternative strategies of supply of these natural products such as bioproduction by microorganisms are needed to ensure stable and massive manufacturing. Here, we developed and optimized yeast cell factories efficiently converting tabersonine to vindoline, a precursor of the major anticancer alkaloids vinblastine and vincristine. First, fine-tuning of heterologous gene copies restrained side metabolites synthesis towards vindoline production. Tabersonine to vindoline bioconversion was further enhanced through a rational medium optimization (pH, composition) and a sequential feeding strategy. Finally, a vindoline titre of 266 mg l−1 (88% yield) was reached in an optimized fed-batch bioreactor. This precursor-directed synthesis of vindoline thus paves the way towards future industrial bioproduction through the valorization of abundant tabersonine resources.

biotechnology & applied microbiology,microbiology
Biosynthesis of catharanthine in engineered Pichia pastoris

Jucan Gao,Yimeng Zuo,Feng Xiao,Yiling Wang,Dongfang Li,Junhao Xu,Cuifang Ye,Linjuan Feng,Leijie Jiang,Tengfei Liu,Di Gao,Bin Ma,Lei Huang,Zhinan Xu,Jiazhang Lian

DOI: https://doi.org/10.1038/s44160-022-00205-2

2023-01-10

Nature Synthesis

Abstract:Catharanthine can be coupled with vindoline to synthesize vinblastine and vincristine, which have been used clinically as potent anticancer drugs. However, the structural complexity and low abundance in nature hamper bulk chemical synthesis and plant extraction, leading to a limited supply and a high cost of this plant natural product. Here, we engineer the methylotrophic yeast Pichia pastoris for complete biosynthesis of catharanthine from simple carbon sources. Through the selection of stable integration sites, screening of biosynthetic pathway enzymes with higher activity and/or specificity, amplification of flux-limiting enzyme encoding genes, rewiring of cellular metabolism and process optimization, we achieve de novo biosynthesis of catharanthine with a titre as high as 2.57 mg l −1 , which also represents the most complicated molecule heterologously synthesized in a non-model microorganism. Our study establishes P. pastoris as a cell factory for producing plant natural products with complex biosynthetic pathways.
Optimization of Tabersonine Methoxylation to Increase Vindoline Precursor Synthesis in Yeast Cell Factories

Pamela Lemos Cruz,Natalja Kulagina,Grégory Guirimand,Johan-Owen De Craene,Sébastien Besseau,Arnaud Lanoue,Audrey Oudin,Nicolas Papon,Marc Clastre,Vincent Courdavault,Nathalie Giglioli-Guivarc'h

DOI: https://doi.org/10.3390/molecules26123596

IF: 4.6

2021-06-11

Molecules

Abstract:Plant specialized metabolites are widely used in the pharmaceutical industry, including the monoterpene indole alkaloids (MIAs) vinblastine and vincristine, which both display anticancer activity. Both compounds can be obtained through the chemical condensation of their precursors vindoline and catharanthine extracted from leaves of the Madagascar periwinkle. However, the extensive use of these molecules in chemotherapy increases precursor demand and results in recurrent shortages, explaining why the development of alternative production approaches, such microbial cell factories, is mandatory. In this context, the precursor-directed biosynthesis of vindoline from tabersonine in yeast-expressing heterologous biosynthetic genes is of particular interest but has not reached high production scales to date. To circumvent production bottlenecks, the metabolic flux was channeled towards the MIA of interest by modulating the copy number of the first two genes of the vindoline biosynthetic pathway, namely tabersonine 16-hydroxylase and tabersonine-16-O-methyltransferase. Increasing gene copies resulted in an optimized methoxylation of tabersonine and overcame the competition for tabersonine access with the third enzyme of the pathway, tabersonine 3-oxygenase, which exhibits a high substrate promiscuity. Through this approach, we successfully created a yeast strain that produces the fourth biosynthetic intermediate of vindoline without accumulation of other intermediates or undesired side-products. This optimization will probably pave the way towards the future development of yeast cell factories to produce vindoline at an industrial scale.

chemistry, multidisciplinary,biochemistry & molecular biology
Efficient production of vindoline from tabersonine by metabolically engineered Saccharomyces cerevisiae

Tengfei Liu,Ying Huang,Lihong Jiang,Chang Dong,Yuanwei Gou,Jiazhang Lian

DOI: https://doi.org/10.1038/s42003-021-02617-w

IF: 6.548

2021-09-16

Communications Biology

Abstract:Abstract Vindoline is a plant derived monoterpene indole alkaloid (MIA) with potential therapeutic applications and more importantly serves as the precursor to vinblastine and vincristine. To obtain a yeast strain for high yield production of vindoline from tabersonine, multiple metabolic engineering strategies were employed via the CRISPR/Cas9 mediated multiplex genome integration technology in the present study. Through increasing and tuning the copy numbers of the pathway genes, pairing cytochrome P450 enzymes (CYPs) with appropriate cytochrome P450 reductases (CPRs), engineering the microenvironment for functional expression of CYPs, enhancing cofactor supply, and optimizing fermentation conditions, the production of vindoline was increased to a final titer as high as ∼16.5 mg/L, which is more than 3,800,000-fold higher than the parent strain and the highest tabersonine to vindoline conversion yield ever reported. This work represents a key step of the engineering efforts to establish de novo biosynthetic pathways for vindoline, vinblastine, and vincristine.

biology
Improved protein glycosylation enabled heterologous biosynthesis of monoterpenoid indole alkaloids and their unnatural derivatives in yeast

Mohammadamin Shahsavarani,Joseph Christian Utomo,Rahul Kumar,Melina Paz-Galeano,Jorge Jonathan Oswaldo Garza-García,Zhan Mai,Dae-Kyun Ro,Yang Qu

DOI: https://doi.org/10.1016/j.mec.2022.e00215

2022-12-05

Abstract:With over 3000 reported structures, monoterpenoid indole alkaloids (MIAs) constitute one of the largest alkaloid groups in nature, including the clinically important anticancer drug vinblastine and its semi-synthetic derivatives from Catharanthus roseus (Madagascar's periwinkle). With the elucidation of the complete 28-step biosynthesis for anhydrovinblastine, it is possible to investigate the heterologous production of vinblastine and other medicinal MIAs. In this study, we successfully expressed the flavoenzyme O-acetylstemmadenine oxidase in Saccharomyces cerevisiae (baker's yeast) by signal peptide modification, which is a vinblastine biosynthetic gene that has not been functionally expressed in this system. We also reported the simultaneous integration of ∼18 kb MIA biosynthetic gene cassettes as single copies into four genomic loci of baker's yeast by CRISPR-Cas9, which enabled the biosynthesis of vinblastine precursors catharanthine and tabersonine from the feedstocks secologanin and tryptamine. We further demonstrated the biosynthesis of fluorinated and hydroxylated catharanthine and tabersonine derivatives using our yeasts, which showed that the MIA biosynthesis accommodates unnatural substrates, and the system can be further explored to produce other complex MIAs.
Total Syntheses and Biological Activities of Vinylamycin Analogues.

Jinghan Wang,Beijia Kuang,Xiaoqian Guo,Jianwei Liu,Yahui Ding,Jiangnan Li,Shende Jiang,Ying Liu,Fang Bai,Luyuan Li,Quan Zhang,Xiao-Yu Zhu,Bo Xia,Chun-Qi Li,Liang Wang,Guang Yang,Yue Chen

DOI: https://doi.org/10.1021/acs.jmedchem.6b01745

IF: 8.039

2017-01-01

Journal of Medicinal Chemistry

Abstract:Natural depsipeptide vinylamycin was reported to be an antibiotic previously. Herein we report vinylamycin to be active against K562 leukemia cells (IC50 = 4.86 μM) and be unstable in plasma (t1/2 = 0.54 h). A total of 24 vinylamycin analogues with modification of the OH group and chiral centers were generated via a combinatorial approach. The lead compound 1a was subsequently characterized as having the following: no antimicrobial activity, significantly higher plasma stability (t1/2 = 14.3 h), improved activity against K562 leukemia cells (IC50 = 0.64 μM), and up to 75% cell inhibition without significant toxicities in K562 cells xenograft zebrafish model. Furthermore, compound 1a maintained its activity against the breast cancer cell line MCF-7 under hypoxic conditions. In comparison, the activity of gemcitabine in the same hypoxic in vitro model of MCF-7 cells was 15-fold lower. Therefore, the present results demonstrate that 1a has great potential as an anticancer agent.
Completion of the seven-step pathway from tabersonine to the anticancer drug precursor vindoline and its assembly in yeast

Yang Qu,Michael L. A. E. Easson,Jordan Froese,Razvan Simionescu,Tomas Hudlicky,Vincenzo De Luca

DOI: https://doi.org/10.1073/pnas.1501821112

IF: 11.1

2015-04-27

Proceedings of the National Academy of Sciences

Abstract:Significance Bioinformatics and virus-induced gene silencing (VIGS)-guided gene discovery combined with biochemical enzyme assays show that tabersonine 3-oxygenase (T3O) and tabersonine 3-reductase (T3R) are required to form 3-hydroxy-16-methoxy-2,3-dihydrotabersonine, an intermediate in the formation of anticancer drug precursor vindoline from tabersonine. In the absence of T3R, tabersonine is converted by T3O to a series of byproducts that can no longer be used by T3R, suggesting a concerted reaction mechanism. Engineering the seven-gene pathway in yeast demonstrated a prototype platform of high potential for industrial production of the anticancer drug precursor vindoline.
Engineering Catharanthus roseus monoterpenoid indole alkaloid pathway in yeast

Vyoma Mistry,Siddhi Darji,Pragya Tiwari,Abhishek Sharma

DOI: https://doi.org/10.1007/s00253-022-11883-5

IF: 5

2022-03-25

Applied Microbiology and Biotechnology

Abstract:Catharanthus roseus (Madagascar periwinkle), a medicinal plant possessing high pharmacological attributes, is widely recognized for the biosynthesis of anticancer monoterpenoid indole alkaloids (MIAs) — vinblastine and vincristine. The plant is known to biosynthesize more than 130 different bioactive MIAs, highly acclaimed in traditional and modern medicinal therapies. The MIA biosynthesis is strictly regulated at developmental and spatial–temporal stages and requires a well-defined cellular and sub-cellular compartmentation for completion of the entire MIAs biosynthesis. However, due to their cytotoxic nature, the production of vinblastine and vincristine occurs in low concentrations in planta and the absence of chemical synthesis alternatives projects a huge gap in demand and supply, leading to high market price. With research investigations spanning more than four decades, plant tissue culture and metabolic engineering (ME)–based studies were attempted to explore, understand, explain, improve and enhance the MIA biosynthesis using homologous and heterologous systems. Presently, metabolic engineering and synthetic biology are the two powerful tools that are contributing majorly in elucidating MIA biosynthesis. This review concentrates mainly on the efforts made through metabolic engineering of MIAs in heterologous microbial factories.Key points• Yeast engineering provides alternative production source of phytomolecules• Yeast engineering also helps to discover missing plant pathway enzymes and genes

biotechnology & applied microbiology
Construction of Canthaxanthin-Producing Yeast by Combining Spatiotemporal Regulation and Pleiotropic Drug Resistance Engineering

Mingkai Chen,Min Li,Lidan Ye,Hongwei Yu

DOI: https://doi.org/10.1021/acssynbio.1c00437

IF: 5.249

2022-01-01

ACS Synthetic Biology

Abstract:The ketocarotenoid canthaxanthin has important applications in the feed industry. Its biosynthesis using microbial cell factories is an attractive alternative to the current chemical synthesis route. Canthaxanthin-producing Saccharomyces cerevisiae was constructed by introducing the beta-carotene ketolase variant OBKTM29 into a beta-carotene producer. Subcellular re-localization of OBKTM29 was explored, together with copy number adjustment both in the cytoplasm and on the periplasmic membrane, to accelerate the conversion of beta-carotene to canthaxanthin. Moreover, pleiotropic drug resistance (PDR) regulators Pdr1 and Pdr3 were overexpressed to improve the stress tolerance of the yeast strain, leading to obviously enhanced canthaxanthin production. The synthetic pathway was then regulated by a temperature-responsive GAL system to separate product synthesis from cell growth. Finally, 1.44 g/L canthaxanthin was harvested in fed-batch fermentation. This work demonstrated the power of spatial and temporal regulation and the efficiency of PDR engineering in heterologous biosynthesis.
A novel approach to the discovery of anti-tumor pharmaceuticals: searching for activators of liponecrosis

Anthony Arlia-Ciommo,Veronika Svistkova,Sadaf Mohtashami,Vladimir I Titorenko

DOI: https://doi.org/10.18632/oncotarget.6440

2016-02-02

Oncotarget

Abstract:A recently conducted chemical genetic screen for pharmaceuticals that can extend longevity of the yeast Saccharomyces cerevisiae has identified lithocholic acid as a potent anti-aging molecule. It was found that this hydrophobic bile acid is also a selective anti-tumor chemical compound; it kills different types of cultured cancer cells if used at concentrations that do not compromise the viability of non-cancerous cells. These studies have revealed that yeast can be successfully used as a model organism for high-throughput screens aimed at the discovery of selectively acting anti-tumor small molecules. Two metabolic traits of rapidly proliferating fermenting yeast, namely aerobic glycolysis and lipogenesis, are known to be similar to those of cancer cells. The mechanisms underlying these key metabolic features of cancer cells and fermenting yeast have been established; such mechanisms are discussed in this review. We also suggest how a yeast-based chemical genetic screen can be used for the high-throughput development of selective anti-tumor pharmaceuticals that kill only cancer cells. This screen consists of searching for chemical compounds capable of increasing the abundance of membrane lipids enriched in unsaturated fatty acids that would therefore be toxic only to rapidly proliferating cells, such as cancer cells and fermenting yeast.
Complete biosynthesis of noscapine and halogenated alkaloids in yeast

Yanran Li,Sijin Li,Kate Thodey,Isis Trenchard,Aaron Cravens,Christina D. Smolke

DOI: https://doi.org/10.1073/pnas.1721469115

IF: 11.1

2018-04-02

Proceedings of the National Academy of Sciences

Abstract:Significance We demonstrate yeast’s capacity for biosynthesis of complex plant natural products by reconstructing a de novo noscapine biosynthetic pathway and optimizing noscapine production toward scalable manufacturing. Engineered strain contains 25 heterologous plant, bacteria, and mammalian genes and 6 mutant or overexpressed yeast genes. The noscapine biosynthetic pathway incorporates seven endomembrane-localized plant enzymes, highlighting yeast’s ability to functionally express and properly localize large numbers of heterologous enzymes into the endoplasm reticulum. Noscapine titers were improved by 18,000-fold (to low mg/L levels) via a combination of enzyme engineering, pathway and strain engineering, and fermentation optimization. We demonstrated that microbial fermentation can be used to produce halogenated alkaloid derivatives, which can ultimately serve as potential drug leads, through feeding amino acid derivatives to strains.
De novo production of the plant-derived alkaloid strictosidine in yeast

Stephanie Brown,Marc Clastre,Vincent Courdavault,Sarah E. O’Connor

DOI: https://doi.org/10.1073/pnas.1423555112

IF: 11.1

2015-02-09

Proceedings of the National Academy of Sciences

Abstract:Significance Plants make a wide variety of complex molecules with potent biological activities including several anticancer therapeutics. Unfortunately, plants often produce these molecules in low amounts, making them expensive to obtain. Engineering simpler organisms, such as yeast, to produce these plant-derived compounds provides one solution to production challenges. One group of plant-derived molecules, the monoterpene indole alkaloids, is synthesized from a common intermediate, strictosidine. Here, we report how we developed a yeast strain that produces strictosidine. This required introducing 21 new genes and three gene deletions into the yeast genome. This yeast strain provides an important resource for the production of expensive, complex molecules that plants normally produce in small amounts.
Engineering the Biosynthesis of Late-Stage Vinblastine Precursors Precondylocarpine Acetate, Catharanthine, Tabersonine in Nicotiana benthamiana

Dagny Grzech,Benke Hong,Lorenzo Caputi,Prashant D. Sonawane,Sarah E. O’Connor

DOI: https://doi.org/10.1021/acssynbio.2c00434

IF: 5.249

2022-12-17

ACS Synthetic Biology

Abstract:ACS Synth Biol . 2022 Dec 14. doi: 10.1021/acssynbio.2c00434. Online ahead of print. NO

biochemical research methods
Completion of the canonical pathway for assembly of anticancer drugs vincristine/vinblastine in Catharanthus roseus

Yang Qu,Olga Safonova,Vincenzo De Luca

DOI: https://doi.org/10.1111/tpj.14111

IF: 7.2

2018-11-10

The Plant Journal

Abstract:The important anticancer drugs, vinblastine, vincristine and analogs, are composed of the monoterpenoid indole alkaloids (MIAs), catharanthine and vindoline, found uniquely in the medicinal plant, Catharanthus roseus. While 26 genes involved in the assembly of these two MIAs are known, two key reactions have eluded characterization to complete the documentation of the vinblastine pathway in this plant species. The assembly of these dimeric MIAs requires O-acetylstemmadenine oxidase (ASO) and a dual function geissoschizine synthase (GS) that reduces cathenamine to form geissoschizine, and that also reduces the ASO product to form a common intermediate for subsequent conversion by four separate hydrolases to catharanthine, tabersonine or vincadifformine, respectively. The in planta role of ASO is supported by identifying a single amino acid-substituted ASO mutant with very low enzyme activity and by virus-induced gene silencing of ASO to produce plants that accumulate O-acetylstemmadenine rather than catharanthine and vindoline found in wild-type (WT) plants. The in planta role of GS is supported by showing that a low GS-expressing mutant accumulating lower levels of catharanthine and vindoline also displays significantly lower tabersonine-forming activity in coupled enzyme assays than in the WT background. Gene expression analyses demonstrate that both ASO and GS are highly enriched in the leaf epidermis where the pathways for catharanthine and tabersonine biosynthesis are expressed. The full elucidation of this canonical pathway enables synthetic biology approaches for manufacturing a broad range of MIAs, including these dimers used in cancer treatment.
Biosynthesis of β-lactam nuclei in yeast

Dameng Yang,Wencheng Su,Yingying Jiang,Shushan Gao,Xiangying Li,Ge Qu,Zhoutong Sun

DOI: https://doi.org/10.1016/j.ymben.2022.02.005

Abstract:We have engineered brewer's yeast as a general platform for de novo synthesis of diverse β-lactam nuclei starting from simple sugars, thereby enabling ready access to a number of structurally different antibiotics of significant pharmaceutical importance. The biosynthesis of β-lactam nuclei has received much attention in recent years, while rational engineering of non-native antibiotics-producing microbes to produce β-lactam nuclei remains challenging. Benefited by the integration of heterologous biosynthetic pathways and rationally designed enzymes that catalyze hydrolysis and ring expansion reactions, we succeeded in constructing synthetic yeast cell factories which produce antibiotic cephalosporin C (CPC, 170.1 ± 4.9 μg/g DCW) and the downstream β-lactam nuclei, including 6-amino penicillanic acid (6-APA, 5.3 ± 0.2 mg/g DCW), 7-amino cephalosporanic acid (7-ACA, 6.2 ± 1.1 μg/g DCW) as well as 7-amino desacetoxy cephalosporanic acid (7-ADCA, 1.7 ± 0.1 mg/g DCW). This work established a Saccharomyces cerevisiae platform capable of synthesizing multiple β-lactam nuclei by combining natural and artificial enzymes, which serves as a metabolic tool to produce valuable β-lactam intermediates and new antibiotics.
Intein-mediated Temperature Control for Complete Biosynthesis of Sanguinarine and Its Halogenated Derivatives in Yeast

Yuanwei Gou,Dongfang Li,Minghui Zhao,Mengxin Li,Jiaojiao Zhang,Yilian Zhou,Feng Xiao,Gaofei Liu,Haote Ding,Chenfan Sun,Cuifang Ye,Chang Dong,Jucan Gao,Di Gao,Zehua Bao,Lei Huang,Zhinan Xu,Jiazhang Lian

DOI: https://doi.org/10.1038/s41467-024-49554-w

IF: 16.6

2024-01-01

Nature Communications

Abstract:While sanguinarine has gained recognition for antimicrobial and antineoplastic activities, its complex conjugated structure and low abundance in plants impede broad applications. Here, we demonstrate the complete biosynthesis of sanguinarine and halogenated derivatives using highly engineered yeast strains. To overcome sanguinarine cytotoxicity, we establish a splicing intein-mediated temperature-responsive gene expression system (SIMTeGES), a simple strategy that decouples cell growth from product synthesis without sacrificing protein activity. To debottleneck sanguinarine biosynthesis, we identify two reticuline oxidases and facilitated functional expression of flavoproteins and cytochrome P450 enzymes via protein molecular engineering. After comprehensive metabolic engineering, we report the production of sanguinarine at a titer of 448.64 mg L−1. Additionally, our engineered strain enables the biosynthesis of fluorinated sanguinarine, showcasing the biotransformation of halogenated derivatives through more than 15 biocatalytic steps. This work serves as a blueprint for utilizing yeast as a scalable platform for biomanufacturing diverse benzylisoquinoline alkaloids and derivatives.
Biosynthesis of -lactam nuclei in yeast

Dameng Yang,Wencheng Su,Yingying Jiang,Shushan Gao,Xiangying Li,Ge Qu,Zhoutong Sun

DOI: https://doi.org/10.1016/j.ymben.2022.02.005

IF: 8.4

2022-01-01

Metabolic Engineering

Abstract:We have engineered brewer's yeast as a general platform for de novo synthesis of diverse 8-lactam nuclei starting from simple sugars, thereby enabling ready access to a number of structurally different antibiotics of significant pharmaceutical importance. The biosynthesis of beta-lactam nuclei has received much attention in recent years, while rational engineering of non-native antibiotics-producing microbes to produce beta-lactam nuclei remains challenging. Benefited by the integration of heterologous biosynthetic pathways and rationally designed enzymes that catalyze hydrolysis and ring expansion reactions, we succeeded in constructing synthetic yeast cell factories which produce antibiotic cephalosporin C (CPC, 170.1 +/- 4.9 mu g/g DCW) and the downstream 8-lactam nuclei, including 6-amino penicillanic acid (6-APA, 5.3 +/- 0.2 mg/g DCW), 7-amino cephalosporanic acid (7-ACA, 6.2 +/- 1.1 mu g/g DCW) as well as 7-amino desacetoxy cephalosporanic acid (7-ADCA, 1.7 +/- 0.1 mg/g DCW). This work established a Saccharomyces cerevisiae platform capable of synthesizing multiple beta-lactam nuclei by combining natural and artificial enzymes, which serves as a metabolic tool to produce valuable beta-lactam intermediates and new antibiotics.

Reprograming Yeast for Anti-Cancer Vinblastine Synthesis

Novel Strategy to Improve Vanillin Tolerance and Ethanol Fermentation Performances of Saccharomycere Cerevisiae Strains.

De Novo Biosynthesis of Vindoline and Catharanthine in Saccharomyces cerevisiae

Fields to fermentors: Brewing botanical chemotherapeutic precursors using genetically engineered yeast

Enhanced bioproduction of anticancer precursor vindoline by yeast cell factories

Biosynthesis of catharanthine in engineered Pichia pastoris

Optimization of Tabersonine Methoxylation to Increase Vindoline Precursor Synthesis in Yeast Cell Factories

Efficient production of vindoline from tabersonine by metabolically engineered Saccharomyces cerevisiae

Improved protein glycosylation enabled heterologous biosynthesis of monoterpenoid indole alkaloids and their unnatural derivatives in yeast

Total Syntheses and Biological Activities of Vinylamycin Analogues.

Completion of the seven-step pathway from tabersonine to the anticancer drug precursor vindoline and its assembly in yeast

Engineering Catharanthus roseus monoterpenoid indole alkaloid pathway in yeast

Construction of Canthaxanthin-Producing Yeast by Combining Spatiotemporal Regulation and Pleiotropic Drug Resistance Engineering

A novel approach to the discovery of anti-tumor pharmaceuticals: searching for activators of liponecrosis

Complete biosynthesis of noscapine and halogenated alkaloids in yeast

De novo production of the plant-derived alkaloid strictosidine in yeast

Engineering the Biosynthesis of Late-Stage Vinblastine Precursors Precondylocarpine Acetate, Catharanthine, Tabersonine in Nicotiana benthamiana

Completion of the canonical pathway for assembly of anticancer drugs vincristine/vinblastine in Catharanthus roseus

Biosynthesis of β-lactam nuclei in yeast

Intein-mediated Temperature Control for Complete Biosynthesis of Sanguinarine and Its Halogenated Derivatives in Yeast

Biosynthesis of -lactam nuclei in yeast